Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib Big Ten Cancer Research Consortium BTCRC-HEM17-092
The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and TAK-659. It will also evaluate the number of patients whose tumor responded after receiving ixazomib and TAK-659.
- IRB Number: 1905960004
- Research Study Identifier: TX10558
- Principal Investigator: Howard Boswell, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required